- Home
- SAN vs PFE Comparison
SAN vs PFE Comparison
Compare SAN & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | PFE |
|---|---|---|
| Founded | 1857 | 1849 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.1B | 145.4B |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAN | PFE |
|---|---|---|
| Price | $11.85 | $25.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $27.40 |
| AVG Volume (30 Days) | 2.6M | ★ 48.9M |
| Earning Date | 02-04-2026 | 02-03-2026 |
| Dividend Yield | 1.56% | ★ 6.87% |
| EPS Growth | 14.58 | ★ 131.89 |
| EPS | 1.00 | ★ 1.73 |
| Revenue | $59,455,590,761.00 | ★ $62,785,000,000.00 |
| Revenue This Year | $23.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $11.19 | $14.55 |
| Revenue Growth | ★ 8.72 | 3.89 |
| 52 Week Low | $4.43 | $20.92 |
| 52 Week High | $11.88 | $27.69 |
Technical Indicators
Market Signals| Indicator | SAN | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 73.61 | 46.09 |
| Support Level | $11.49 | $24.83 |
| Resistance Level | $11.78 | $25.52 |
| Average True Range (ATR) | 0.15 | 0.56 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 98.95 | 11.81 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.